ClinicalTrials.gg
TerminatedNCT00348712Updated Mar 1, 2017

Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

A Phase 3 interventional study of rosiglitazone and inhaled human insulin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 74 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-01.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
See termination reason in detailed description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.

Enrollment
17th of 51
301 · median 149
Started
2006
with 7 others
Phase 3
21 of 52
none open now
Registered
26th of 52
by date
Lead sponsor
4 of 52
Novo Nordisk A/S

Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment of the 51 interventional ones that give a count, is one of 8 that started in 2006, is one of 21 in phase 3, and was the 26th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rosiglitazone

Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This trial is conducted in Europe.

The aim of this research study is to compare the efficacy of adding inhaled preprandial insulin to metformin compared to adding rosiglitazone to metformin for the treatment of type 2 diabetes and to verify its safety (hypoglycaemia, pulmonary function, body weight, insulin antibodies and side effects).

Read the detailed description

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 301 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Treated with OAD(s) for more than or equal to 2 months
  • of (BMI) less than or equal to 40.0 kg/m2
  • greater than or equal to 7.5% and less than or equal to 11.0 % for subjects in OAD monotherapy and HbA1c greater than or equal to 7.0% and less than or equal to 10.0 % for subjects on OAD combination therapy

Exclusion criteria

Exclusion Criteria:

  • Recurrent major hypoglycaemia
  • Current smoking or smoking within the last 6 months
  • Impaired hepatic or renal function
  • Cardiac disorders
  • Uncontrolled hypertension
  • Proliferative retinopathy or maculopathy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
301 participants (actual)

Study arms

  • Active comparator
    A

    Drug: inhaled human insulin · Drug: metformin

  • Active comparator
    B

    Drug: rosiglitazone · Drug: metformin

Interventions

07

What researchers measure

Primary outcomes

  1. Treatment difference in HbA1c

    Time frame: After 26 weeks

Secondary outcomes

  1. Adverse events

    Time frame: For the duration of the trial

  2. Body weight

    Time frame: For the duration of the trial

  3. Lung function

    Time frame: For the duration of the trial

  4. Blood glucose

    Time frame: For the duration of the trial

  5. Hypoglycaemia

    Time frame: For the duration of the trial

08

Study locations

74 sites
  • Novo Nordisk Investigational Site
    Ebreichsdorf, 2483, Austria
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, 1090, Austria
  • Novo Nordisk Investigational Site
    Joensuu, 80130, Finland
  • Novo Nordisk Investigational Site
    Kirkkonummi, 02400, Finland
  • Novo Nordisk Investigational Site
    Turku, FI-20520, Finland
  • Novo Nordisk Investigational Site
    Corbeil Essonnes, 91106, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Mougins, 06250, France
  • Novo Nordisk Investigational Site
    Nanterre, 92014, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    NEVERS cedex, 58033, France
  • Novo Nordisk Investigational Site
    Pessac, 33600, France
  • Novo Nordisk Investigational Site
    Pointe à Pitre, 97159, France
  • Novo Nordisk Investigational Site
    Roubaix, 59100, France
  • Novo Nordisk Investigational Site
    Tours, 37044, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Aschaffenburg, 63739, Germany
  • Novo Nordisk Investigational Site
    Augsburg, 86150, Germany
  • Novo Nordisk Investigational Site
    Bad Mergentheim, 97980, Germany
  • Novo Nordisk Investigational Site
    Berlin, 13355, Germany
  • Novo Nordisk Investigational Site
    Darmstadt, 64283, Germany
  • Novo Nordisk Investigational Site
    Dormagen, 41539, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01307, Germany
  • Novo Nordisk Investigational Site
    Duisburg, 47051, Germany
  • Novo Nordisk Investigational Site
    Flörsheim, 65439, Germany
  • Novo Nordisk Investigational Site
    Frankfurt, 60590, Germany
  • Novo Nordisk Investigational Site
    Fulda, 36037, Germany
  • Novo Nordisk Investigational Site
    Genthin, 39307, Germany
  • Novo Nordisk Investigational Site
    Hermaringen, 89568, Germany
  • Novo Nordisk Investigational Site
    Kutenholz-Mulsum, 27449, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Pirna, 01796, Germany
  • Novo Nordisk Investigational Site
    Schkeuditz, 04435, Germany
  • Novo Nordisk Investigational Site
    Wangen, 88239, Germany
  • Novo Nordisk Investigational Site
    Wiesbaden, 65191, Germany
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 7, Ireland
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 8, Ireland
  • Novo Nordisk Investigational Site
    Waterford, Ireland
  • Novo Nordisk Investigational Site
    Delft, 2625 AD, Netherlands
  • Novo Nordisk Investigational Site
    Den Haag, 2582 LJ, Netherlands
  • Novo Nordisk Investigational Site
    Den Haag, 2597 AX, Netherlands
  • Novo Nordisk Investigational Site
    Drachten, 9202 NN, Netherlands
  • Novo Nordisk Investigational Site
    Rijswijk, 2281 AK, Netherlands
  • Novo Nordisk Investigational Site
    Roelofarendsveen, 2371 RB, Netherlands
  • Novo Nordisk Investigational Site
    Vlodrop, 6063 DA, Netherlands
  • Novo Nordisk Investigational Site
    Zwijndrecht, 3331 LZ, Netherlands
  • Novo Nordisk Investigational Site
    Alcira, 46600, Spain
  • Novo Nordisk Investigational Site
    Barcelona, 08035, Spain
  • Novo Nordisk Investigational Site
    Gijón, 33206, Spain
  • Novo Nordisk Investigational Site
    Majadahonda, 28222, Spain
  • Novo Nordisk Investigational Site
    Palma de Mallorca, 07010, Spain
  • Novo Nordisk Investigational Site
    Partida de Bacarot, 03114, Spain
  • Novo Nordisk Investigational Site
    Pontevedra, 36071, Spain
  • Novo Nordisk Investigational Site
    Reus, 43201, Spain
  • Novo Nordisk Investigational Site
    San Juan, 03550, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41009, Spain
  • Novo Nordisk Investigational Site
    Interlaken-Unterseen, 3800, Switzerland
  • Novo Nordisk Investigational Site
    Olten, 4600, Switzerland
  • Novo Nordisk Investigational Site
    Zürich, 8032, Switzerland
  • Novo Nordisk Investigational Site
    Aberdeen, AB25 1LD, United Kingdom
  • Novo Nordisk Investigational Site
    Bath, BA1 2SR, United Kingdom
  • Novo Nordisk Investigational Site
    Belfast, BT12 6BA, United Kingdom
  • Novo Nordisk Investigational Site
    Birmingham, B9 5SS, United Kingdom
  • Novo Nordisk Investigational Site
    Bradford-on-Avon, BA15 1DQ, United Kingdom
  • Novo Nordisk Investigational Site
    Guildford, GU2 7XX, United Kingdom
  • Novo Nordisk Investigational Site
    Hull, HU3 2JZ, United Kingdom
  • Novo Nordisk Investigational Site
    Northampton, NN1 5BD, United Kingdom
  • Novo Nordisk Investigational Site
    Salford, M6 8HD, United Kingdom
  • Novo Nordisk Investigational Site
    Swansea, SA6 6NL, United Kingdom
  • Novo Nordisk Investigational Site
    Trowbridge, BA14 8QA, United Kingdom
  • Novo Nordisk Investigational Site
    Trowbridge, BA14 9AR, United Kingdom
  • Novo Nordisk Investigational Site
    Wirral, Merseyside, CH63 4JY, United Kingdom
  • Novo Nordisk Investigational Site
    York, YO3 7HE, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2006 to primary completion in Mar 2008, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2006
First posted
Jul 6, 2006
StartActual
Oct 30, 2006
Primary completionActual
Mar 5, 2008
CompletionActual
Mar 5, 2008
Last update
Mar 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00348712
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 6, 2006
Start date
Oct 30, 2006
Primary completion
Mar 5, 2008
Completion
Mar 5, 2008
Last update
Mar 1, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosiglitazone · Insulin, Regular, Human

Start the discussion